Annual price review of medicines for 2025
The recent Administrative Ruling no. 293/2024/1, of November 15 established the regime for the annual price review of medicines purchased by services of the National Health System (SNS) and medicines delivered within the scope of the OTC market, including generic and biosimilar medicines, for the year 2025.
Did you find this article useful?
Download PDF